Cambridge Investment Research Advisors Inc. Grows Position in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH)

Cambridge Investment Research Advisors Inc. raised its position in First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) by 19.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,567 shares of the company’s stock after acquiring an additional 2,663 shares during the quarter. Cambridge Investment Research Advisors Inc. owned approximately 3.01% of First Trust Nasdaq Pharmaceuticals ETF worth $455,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. NBC Securities Inc. lifted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 21,400.0% in the first quarter. NBC Securities Inc. now owns 1,075 shares of the company’s stock valued at $29,000 after acquiring an additional 1,070 shares during the period. Vivaldi Capital Management LP raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the fourth quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock worth $243,000 after buying an additional 1,171 shares during the period. Summit Investment Advisors Inc. raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock worth $382,000 after buying an additional 1,633 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 17.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock worth $442,000 after buying an additional 2,384 shares during the period. Finally, LPL Financial LLC raised its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.3% in the fourth quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock worth $1,507,000 after buying an additional 4,776 shares during the period.

First Trust Nasdaq Pharmaceuticals ETF Stock Up 1.2%

NASDAQ FTXH opened at $26.81 on Friday. The stock’s 50-day moving average price is $25.62 and its 200-day moving average price is $26.45. First Trust Nasdaq Pharmaceuticals ETF has a 52 week low of $23.29 and a 52 week high of $29.72. The company has a market capitalization of $14.75 million, a P/E ratio of 14.51 and a beta of 0.70.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Thursday, June 26th were paid a $0.0892 dividend. This represents a $0.36 annualized dividend and a dividend yield of 1.33%. The ex-dividend date was Thursday, June 26th.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.